Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
System-State: Number of processed items 17.070 Notifications successully processed since Inception
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US1101221083
State: 24.11.2024 | 6PM
Do you already know our new terminal view? Click here.
FIGI: BBG000DQLV23
BMY
Bristol-Myers Squibb Company
GICS: - · Sector: Healthcare · Sub-Sector: Drug Manufacturers—General
NAME
Bristol-Myers Squibb Company
ISIN
US1101221083
TICKER
BMY
MIC
XNYS
REUTERS
BMY.N
BLOOMBERG
BMY US
Tue, 19.11.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 90 data disclosures, including 18 oral presentations, across company-sponsored studies, investigator-sponsored studies and collaborations from its hematology and cell therapy research programs at the 66th American Society of Hematology (ASH) Annual Meeting and Expositio...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Fri, 15.11.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dM...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Fri, 15.11.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for repotrectinib, a next-generation tyrosine kinase inhibitor (TKI), as a treatment for adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) and fo...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Mon, 11.11.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific Sessions, taking place November 16-18, 2024, in Chicago, Illinois. New analyses include updated results from the nearly two-year post-launch evaluation of the CAMZYOS® (mavacamten) ...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.11.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024. Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer and Head of Development, and Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer, will take part in a fireside chat ...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Thu, 31.10.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of COBENFY™ (xanomeline and trospium chloride) in adults with schizophrenia over 52 weeks of treatment. Data were presented at the 2024 Psych Congress, taking ...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Thu, 31.10.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today reports results for the third quarter of 2024. “We made important strides in the third quarter with the landmark U.S. approval of Cobenfy in schizophrenia, continued sales momentum, strong cash flow generation and key pipeline achievements,” said Christopher Boerner, Ph.D., board chair and chief executive of...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Mon, 28.10.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating COBENFY™ (xanomeline and trospium chloride) in schizophrenia in adults will be presented at Psych Congress 2024, taking place October 29 – November 2 in Boston, Massachusetts. “Bui...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Thu, 03.10.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) for the treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rear...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Fri, 27.09.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE:BMY) today announced positive results from the Phase 3b/4 PSORIATYK SCALP trial evaluating Sotyktu (deucravacitinib) for the treatment of patients with moderate-to-severe scalp psoriasis, including those with less extensive overall psoriasis. The primary endpoint was met, with a statistically significant improvement in t...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Fri, 27.09.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.1 COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating s...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Wed, 18.09.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients treated with Zeposia (ozanimod) for relapsing forms of multiple sclerosis. These findings showed that patients receiving continuous Zeposia t...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Sun, 15.09.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced 10-year follow-up data from CheckMate -067, a randomized, double-blind, Phase 3 clinical trial, which showed continued durable improvement in survival with first-line Opdivo® (nivolumab) plus Yervoy® (ipilimumab) therapy and Opdivo monotherapy, versus Yervoy alone, in patients with previously untrea...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Thu, 12.09.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2024 on Thursday, October 31, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Tue, 10.09.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on November 1, 2024, to stockholders of record at the close of business on October 4, 2024. In addition, the Board of Directors ...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Mon, 09.09.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of nearly 60 abstracts of company-sponsored studies, investigator-sponsored studies, and collaborations from across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2024 to be held from September 13-17 in Barcelona, Spain. “Our data a...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Sun, 01.09.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating CAMZYOS® (mavacamten) in adult patients with New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The long-term follow-up effica...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Tue, 27.08.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in September 2024. Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer, and David Elkins, Executive Vice President, Chief Financial Officer, will take part in a fireside chat at the Morgan Stanley 22nd Annual Gl...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Mon, 26.08.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 30 – September 2, 2024, in London, England. Data to be presented at the meeting includes long-term extension data evaluating the efficacy and safety profi...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink
Wed, 21.08.2024       Bristol-Myers Squibb
US1101221083

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as potential first-line treatment for adult patients with unresectable hepatocellular carcinoma (HCC), based on results from the Phase...
Read More
Bristol-Myers Squibb
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.